Expanded Access Program (EAP) for Galinpepimut-S (GPS) in Patients Diagnosed With AML or MDS
- Conditions
- Acute Myeloid LeukemiaMyelodysplastic Syndromes
- First Posted Date
- 2022-10-25
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Sellas Life Sciences Group
- Registration Number
- NCT05593185
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies
Phase 1
Recruiting
- Conditions
- Hematologic Malignancies
- Interventions
- First Posted Date
- 2020-10-19
- Last Posted Date
- 2024-06-14
- Lead Sponsor
- Sellas Life Sciences Group
- Target Recruit Count
- 160
- Registration Number
- NCT04588922
- Locations
- 🇺🇸
MD Anderson, Houston, Texas, United States
🇨🇳Linyi Cancer Hospital, Linyi, Shandong, China
🇨🇳The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China
Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2
Phase 3
Active, not recruiting
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Biological: Galinpepimut-SDrug: AzacitidineBiological: GM-CSFDrug: VenetoclaxOther: MontanideDrug: DecitabineDrug: CytarabineOther: Observation
- First Posted Date
- 2020-01-18
- Last Posted Date
- 2024-04-09
- Lead Sponsor
- Sellas Life Sciences Group
- Target Recruit Count
- 128
- Registration Number
- NCT04229979
- Locations
- 🇺🇸
Mayo Clinic Jacksonville Florida, Jacksonville, Florida, United States
🇫🇷CHU de Caen, Caen, France
🇬🇷General Hospital of Athens "Evaggelismos", Athens, Greece
Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers
Phase 1
Completed
- Conditions
- Acute Myelogenous LeukemiaOvarian CancerColorectal CancerTriple-negative Breast CancerSmall-cell Lung Cancer
- Interventions
- First Posted Date
- 2018-12-03
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Sellas Life Sciences Group
- Target Recruit Count
- 26
- Registration Number
- NCT03761914
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸St. Joseph Heritage Healthcare, Santa Rosa, California, United States
🇺🇸Innovative Clinical Research Institute (ICRI), Whittier, California, United States
WT1 Analog Peptide Vaccine in Patients With Multiple Myeloma Following Autologous Stem Cell Transplantation
Not Applicable
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2013-04-09
- Last Posted Date
- 2020-01-10
- Lead Sponsor
- Sellas Life Sciences Group
- Target Recruit Count
- 22
- Registration Number
- NCT01827137
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
WT1 Vaccine Treatment of Patients in Remission From Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL)
Phase 2
Completed
- Conditions
- Acute Myeloid LeukemiaAcute Lymphoblastic Leukemia
- Interventions
- First Posted Date
- 2010-12-24
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Sellas Life Sciences Group
- Target Recruit Count
- 22
- Registration Number
- NCT01266083
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Galinpepimut-S (WT-1 Analog Peptide) Vaccine in Malignant Pleural Mesothelioma After Combined Modality Therapy
Phase 2
Completed
- Conditions
- Malignant Pleural Mesothelioma
- Interventions
- Biological: Galinpepimut-S + Montanide + GM-CSFBiological: Montanide + GM-CSF
- First Posted Date
- 2010-12-23
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- Sellas Life Sciences Group
- Target Recruit Count
- 41
- Registration Number
- NCT01265433
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
© Copyright 2025. All Rights Reserved by MedPath